Welcome to our dedicated page for CervoMed SEC filings (Ticker: CRVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to CervoMed Inc. (NASDAQ: CRVO) SEC filings, offering a detailed view of how the clinical-stage biotechnology company reports its operations, financial condition, and development plans for neflamapimod and related programs. As a NASDAQ Capital Market issuer, CervoMed files current reports on Form 8-K, annual reports on Form 10-K, and other documents that outline its progress in dementia with Lewy bodies (DLB) and other age-related brain disorders.
In recent Form 8-K filings, CervoMed has furnished press releases covering quarterly financial results, new clinical data from the Phase 2b RewinD-LB trial, and written feedback from the U.S. Food and Drug Administration on the design of its planned Phase 3 trial in DLB. These filings describe how the company plans to use endpoints such as change in Clinical Dementia Rating – Sum of Boxes (CDR-SB), enrichment strategies based on plasma ptau181, and biomarker assessments like glial fibrillary acidic protein (GFAP) to support a potential New Drug Application for neflamapimod.
Other 8-Ks document corporate governance events, including the appointment of new directors and executive officers, adoption of equity incentive plans, and stock option grants. Filings relating to the annual meeting of stockholders detail voting outcomes on director elections, auditor ratification, advisory votes on executive compensation, and approval of equity plans. Together, these documents provide a structured record of CervoMed’s governance, capital structure, and incentive arrangements.
Through Stock Titan, users can review these SEC filings alongside AI-powered summaries that explain key sections in plain language. Real-time updates from EDGAR help surface new 8-Ks, 10-Qs, and 10-Ks as they are filed, while AI-generated highlights can point to important disclosures on clinical trial results, regulatory milestones, grant funding, and risk factors. Investors can also use the filings page to monitor how CervoMed describes its lead program, neflamapimod, and its broader strategy in age-related brain disorders over time.
CervoMed Inc. announced that its lead drug candidate, neflamapimod, has been selected for inclusion in the UK-based EXPERTS-ALS platform, which rapidly tests potential treatments for amyotrophic lateral sclerosis (ALS) using biomarker-based trials. This will be the first clinical evaluation of neflamapimod in ALS.
Neflamapimod, an oral small molecule that crosses the blood–brain barrier and selectively inhibits p38 MAP kinase, will initially be studied in approximately 35 ALS participants for 18–24 weeks, with possible expansion to up to 80 patients. The trial will measure changes in blood neurofilament light chain, a marker linked to neuroaxonal damage and ALS progression, and include clinical and survival endpoints.
Trial costs in EXPERTS-ALS are funded by the UK National Institute for Health and Care Research and leading motor neuron disease charities, while CervoMed continues to focus on dementia with Lewy bodies (DLB) and plans a global Phase 3 DLB trial in the second half of 2026, subject to available funding.
CervoMed Inc. reported that Chief Commercial and Business Officer Matthew Winton received a grant of stock options. On February 11, 2026, he was awarded options to acquire 30,000 shares of CervoMed common stock at an exercise price of $4.8 per share.
The award vests in 36 roughly equal monthly installments, with vesting starting on February 28, 2026 and continuing on the last calendar day of each month over three years. All 30,000 derivative securities are reported as directly owned following this grant.
CervoMed Inc. reported an indirect insider award linked to director and 10% owner Sylvie Gregoire. A derivative position of 75,000 stock options with a $4.80 exercise price was granted on February 11, 2026 to her spouse, John Alam, the company’s President & Chief Executive Officer.
The options relate to 75,000 shares of common stock and were reported at a cost of $0 for the derivative itself, with 75,000 derivative securities beneficially owned after the transaction as indirect ownership "By Spouse." The filing states that Gregoire disclaims beneficial ownership. The underlying shares will vest in 36 monthly installments beginning February 28, 2026.
ELDER WILLIAM ROBERT reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 30,000 shares. Following the reported transactions, holdings were 30,000 shares.
De Rosch Mark reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 30,000 shares. Following the reported transactions, holdings were 30,000 shares.
Blackburn Kelly reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 30,000 shares. Following the reported transactions, holdings were 30,000 shares.
ALAM JOHN J reported acquisition or exercise transactions in a Form 4 filing for CRVO. The filing lists transactions totaling 75,000 shares. Following the reported transactions, holdings were 75,000 shares.
Morgan Stanley and its affiliate Morgan Stanley Capital Services LLC have filed a Schedule 13G reporting beneficial ownership of CervoMed Inc. common stock. Morgan Stanley reports beneficial ownership of 473,681 shares, representing 5.1% of CervoMed’s common stock as of the event date.
Morgan Stanley Capital Services LLC reports beneficial ownership of 470,631 shares, also representing 5.1% of the class, with shared voting and dispositive power over these shares. The filing states the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of CervoMed.
CervoMed Inc. reported that it has made an investor presentation available on its website under the “Investors – Events and Presentations” section. Company representatives may use this presentation in meetings and conferences with investors, analysts and others, with possible non-material updates over time.
The presentation is described as summary information meant to be read together with CervoMed’s other SEC filings and public announcements. The company states it has no obligation to update the presentation except as required by law, and clarifies that the information is being furnished under Regulation FD rather than filed, so it is not subject to certain Exchange Act liabilities nor automatically incorporated into other securities filings.
CervoMed Inc. officer reports open-market stock purchases
An officer of CervoMed Inc. (CRVO), serving as Chief Commercial and Business leader, reported buying company common stock in open-market transactions. On 11/17/2025, the officer purchased 3,500 shares at a price of $8.43 per share. On 11/18/2025, the officer purchased an additional 1,500 shares at $7.95 per share.
After these transactions, the officer beneficially owns a total of 15,000 shares of CervoMed common stock, held directly. The filing indicates that the reported transactions were regular stock purchases rather than option exercises or other derivative security activity.